Literature DB >> 11101358

4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.

H Shinkai1, T Ito, T Iida, Y Kitao, H Yamada, I Uchida.   

Abstract

Small-molecule nociceptin antagonists were synthesized to examine their therapeutic potential. After a 4-aminoquinoline derivative was found to bind with the human ORL(1) receptor, a series of 4-aminoquinolines and related compounds were synthesized and their binding was evaluated. Elucidation of structure-activity relationships eventually led to the optimum compounds. One of these compounds, N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride (11) not only antagonized nociceptin-induced allodynia in mice but also showed analgesic effect in a hot plate test using mice and in a formalin test using rats. Its analgesic effect was not antagonized by the opioid antagonist naloxone. These results indicate that this nociceptin antagonist has the potential to become a novel type of analgesic that differs from mu-opioid agonists.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101358     DOI: 10.1021/jm0002073

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  One-pot tandem Ugi-4CR/S(N)Ar approach to highly functionalized quino[2,3-b][1,5]benzoxazepines.

Authors:  Mehdi Ghandi; Nahid Zarezadeh; Alireza Abbasi
Journal:  Mol Divers       Date:  2015-12-24       Impact factor: 2.943

Review 2.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

3.  Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.

Authors:  Nurulain T Zaveri; Faming Jiang; Cris Olsen; Willma E Polgar; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2013-04-04       Impact factor: 2.823

4.  Pharmacological profiles of a novel opioid receptor-like1 (ORL(1)) receptor antagonist, JTC-801.

Authors:  Hideki Yamada; Hiromitsu Nakamoto; Yasunori Suzuki; Takao Ito; Kazuo Aisaka
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 5.  Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

6.  The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.

Authors:  Ling Jong; Nurulain Zaveri; Lawrence Toll
Journal:  Bioorg Med Chem Lett       Date:  2004-01-05       Impact factor: 2.823

7.  Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice.

Authors:  Tomohiro Koyama; Kazuhiko Fukuda
Journal:  J Anesth       Date:  2009-05-15       Impact factor: 2.078

8.  2-Amino-5-chloro-pyridinium 2-carb-oxy-acetate.

Authors:  Madhukar Hemamalini; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-05-29

9.  Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.

Authors:  Zhe Ding; Robert B Raffa
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

10.  In vitro and ex vivo effects of a selective nociceptin/orphanin FQ (N/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N/OFQ and [35S]GTPgammaS in rat brain and spinal cord.

Authors:  Shizuo Yamada; Toyofumi Kusaka; Akihiko Urayama; Ryohei Kimura; Yasuo Watanabe
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.